Advertisement
Advertisement
U.S. Markets open in 9 hrs 2 mins
Advertisement
Advertisement
Advertisement
Advertisement

TScan Therapeutics, Inc. (TCRX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.02-0.78 (-10.00%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.80
Open7.60
Bid7.00 x 800
Ask7.30 x 900
Day's Range7.01 - 7.69
52 Week Range6.06 - 14.71
Volume22,864
Avg. Volume66,906
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.67
  • GlobeNewswire

    TScan Therapeutics to Participate in Upcoming Investor Conferences

    WALTHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate virtually at the following upcoming investor conferences: Jefferies London Healthcare Conference; the fireside chat will be available for on-demand listening beginning Thursday, November 18, 2021, at

  • GlobeNewswire

    TScan Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

    IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Therapy Candidates TSC-100 and TSC-101 Lead TCR Identified for TSC-200 Solid Tumor Program Targeting HPV16; TCR Advancing into IND-Enabling Activities with IND Submission Planned for Second Half of 2022 New Solid Tumor Program, TSC-204, Established Based on a TCR Targeting an HLA-C*07:02 Epitope of MAGE-A1 WALTHAM, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical compa

  • GlobeNewswire

    TScan Therapeutics Announces Upcoming Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition

    WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that two abstracts related to its lead liquid tumor candidates TSC-100 and TSC-101 have been accepted for poster presentations at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition, being held from Decembe

Advertisement
Advertisement